Status:
RECRUITING
The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection
Lead Sponsor:
Ain Shams University
Conditions:
Pulmonary Hydatid Cyst
Eligibility:
All Genders
Phase:
NA
Brief Summary
The aim of this study is to study the role of adjuvant Albendazole after pulmonary hydatid cyst resection versus placebo in reducing recurrence with a short- term follow-up of six months.
Detailed Description
Hydatid disease, also referred to as cystic echinococcosis, is a major zoonotic disease with global distribution caused by the larval stage of the Echinococcus parasite, which belongs to the Taeniidae...
Eligibility Criteria
Inclusion
- All patients regardless of age with pulmonary hydatid disease requiring surgical resection.
- Patients achieving complete resection of pulmonary hydatid disease.
- Patients with no extra pulmonary hydatid disease.
- Patients who have received preoperative albendazole.
Exclusion
- Patients with extra pulmonary hydatid disease requiring treatment after pulmonary resection.
- Patients with incomplete resection of pulmonary hydatid disease.
- Patients with pulmonary hydatid disease not amenable for resection.
- Patients with hypersensitivity to Albendazole.
- Patients with liver dysfunction.
- Patients refusing to be enrolled in the study.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06483880
Start Date
February 1 2024
End Date
July 1 2025
Last Update
February 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Al Abbasiya, Egypt